InflaRx N.V. (NASDAQ: IFRX) presented data from its Phase 3 study of vilobelimab for pyoderma gangrenosum during a late-breaking research session at the 2026 American Academy of Dermatology Annual Meeting in Denver.

The study enrolled 54 patients before being terminated early due to futility following an Independent Data Monitoring Committee recommendation. The primary endpoint of complete target ulcer closure was achieved by 20.8% of vilobelimab patients versus 16.7% on placebo. Complete disease remission occurred in 20.8% of vilobelimab patients compared to 5.1% of placebo patients.

Over one-third of vilobelimab-treated patients achieved more than a 50% reduction in ulcer volume compared with 16.7% of patients receiving placebo. The treatment reduced C5a levels by a mean of 76.6% from baseline compared to 13.5% with placebo.

Vilobelimab was generally well tolerated, with most adverse events reported as mild to moderate. Serious adverse events occurred in 6.3% of vilobelimab patients and 4.5% of placebo patients.

"The data reinforce the biological rationale behind vilobelimab and suggest that it may have meaningful potential for patients suffering from neutrophilic diseases where the C5a/C5aR pathway plays a role," said Camilla Chong, Chief Medical Officer of InflaRx.

The company is currently prioritizing discussions with the FDA regarding izicopan for hidradenitis suppurativa treatment. InflaRx anticipates meeting with the FDA to determine a potential development path for vilobelimab in pyoderma gangrenosum, with any future development activities likely conducted in collaboration with a partner.

Vilobelimab is a monoclonal antibody that blocks complement factor C5a while preserving the membrane attack complex as a defense mechanism of the innate immune system.